• The FDA-approved prescribing information was used to guide the evaluation.
• The actual change from baseline for active vs placebo vehicle control was then compared to the Barnes MCID threshold estimate. 5 • The term "minimal clinically important difference" (MCID) was described by Jaeschke, Singer, and Guyatt in 1989.
The Importance of Anchor-based Minimal Clinically Important Difference to Health Technology Assessment of Established Intranasal Allergic Rhinitis Treatments
• Subsequent work by others refined threshold estimates for MCID to a variety of disease-specific patient-reported outcome (PRO) measures.
• As the science evolved, MCID threshold estimation techniques have centered around 3 different methodologies (Table 1) , with anchor-based methods considered by some to be one of the more robust estimation methodologies.
• Specific to technology assessment of alternative seasonal allergic rhinitis (SAR) treatments, the Agency for Healthcare Research and Quality (AHRQ) used MCID threshold estimates provided from a technical expert panel; these results may have been interpreted to suggest that treatment options for SAR are equivalent to placebo, which is in direct conflict with evidence-based practice parameters and clinical practice.
• To date, no systematic health technology assessment has been reported using anchor-based MCID threshold estimates to demonstrate if frequently used intra-nasal treatment can be demonstrated to provide a clinically meaningful difference.
BACKGROUND
The objective of this evaluation is to compare the outcomes of an anchor-based vs non-anchor-based methodology in the health technology assessment of intranasal allergic rhinitis treatments.
OBJECTIVES INCLUSION AND EXCLUSION CRITERIA
4 products met the inclusion and exclusion criteria below (Table 2) • Inclusion Criteria -Intranasal treatment options using alternative active ingredients but approved and routinely used in clinical practice for the treatment of individuals with SAR -Dosing for the treatment of SAR included in the prescribing information -Data related to the change from baseline in the reflective Total Nasal Symptom Score (rTNSS) available within the approved prescribing information -Pivotal trials compared active treatment to placebo (vehicle) • Exclusion Criteria -Oral agents used for the treatment of individuals with SAR -Intranasal agents only approved for the treatment of perennial allergic rhinitis -Intranasal agents approved using PRO data other than that derived using the rTNSS • The AHRQ report used technical panel estimates for MCID.
• The panel concluded that 30% of the maximum score (ie, 3.6 units) is a useful threshold that can be applied across symptom scales.
• Using the threshold of 30%, the authors suggested that some treatment options could not be reported to have a clinically meaningful benefit. Anchor-based MCID Estimates • Using the most conservative estimates provided within the approved prescribing information, the change in rTNSS from baseline was −2.01 (P<0.001) for azelastine hydrochloride, −1.35 (P=0.014) for ciclesonide, −2.07 (P<0.001) for fluticasone furoate, and −2.7* for single-formulation MP-AzeFlu (P<0.001).
• Direct anchor-based estimates of MCID derived by Barnes • In contrast, the AHRQ report implied that treatment options were equivalent to each other, to intranasal corticosteroids, and to placebo, in contrast to common patient beliefs.
* Range of rTNSS is 0-12; 0-24 for MP-AzeFlu. Table 1 . An Overview of the 3 Most Common MCID Estimation Techniques
Anchor-based MCID Estimation
Does not only consider the precision of an instrument and looks at the relationship between the outcome of interest and an independent, patient-specific variable
Distribution-based MCID Estimation
Assesses the measurement precision of a given patient-reported outcome measure, is sample-dependent, and does not provide external validity for assessing clinical relevance
Technical Expert Panel Estimation
Uses expert opinion to guide determination of MCID but variation can exist across experts 
CONCLUSIONS
• The use of MCID can assist in the determination of whether or not a given benefit may be clinically meaningful.
• Clinical and reimbursement decisions should consider all existing and available MCID methods, that generate MCID estimates in technology assessments.
• When available, anchor-based MCID methods, that generate MCID estimates, will provide the most robust estimate of whether a benefit is clinically meaningful.
• With respect to the evaluation of intranasal treatment options for SAR, MCID threshold estimates derived from technical expert opinion as presented in the AHRQ report are not corroborated by anchor-based MCID techniques.
• Therefore, re-evaluation and revision of existing comparative reports using technical expert opinion may be warranted since anchor-based methods suggest that a clinically meaningful benefit is derived from the use of intranasal treatment options for SAR.
